Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Mexico for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Mexico only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Mexico (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mark Chiu (NPI 1821083932)

Field	Value
Entity Type	Individual
Organization	Mark Chiu
Address	806 Dr Martin Luther King Jr Ave Ne
City	Albuquerque
State	NM
ZIP	87102
Taxonomy	Ophthalmology Physician
NPI Enumerated	September 14, 2005

Payer Source	Total Paid
Medicare	$3.8M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the clear business driver: lifetime Medicare revenue is $3.8M while there is no Medicaid billing on file, so the practice is effectively single-payer in the public programs and reliant on Medicare volume and reimbursements for its public-payor revenue base. Analysts should treat Medicaid as non-contributory for payer-mix modeling and network planning for this NPI.

Revenue concentration is very high: the precomputed top 3 Medicare codes by revenue account for 83.8% of this provider's total Medicare revenue, driven by J0178 (42.9%), J2777 (34.6%), and J2778 (6.3%). This indicates that a small set of intravitreal drug codes make up the vast majority of public-payor receipts.

The code mix signals a retina-focused ophthalmology operation: the largest single revenue sources are intravitreal biologic administrations (J0178 – aflibercept, 2.4K claims, $1.6M revenue; J2777 – faricimab, 45.4K claims, $1.3M revenue; J2778 – ranibizumab, 1.3K claims, $238.2K revenue) and related eye injection procedures such as 67028 (2.4K claims, $212.8K revenue). The presence of high-volume imaging with 92134 (1.6K claims, $43.6K revenue) and a substantive number of intravitreal implant codes (J7312) reinforces a procedure-heavy retina practice rather than a primarily general ophthalmology office.

Competitive standing on key injectable drugs is mixed: J0178 ranks #375 of 3204 providers nationally (88th percentile; typical, unremarkable volume for this code) and J2777 ranks #134 of 2039 providers nationally (93th percentile; typical, unremarkable volume for this code), so the provider is a solid national participant for these drugs but not an extreme outlier or market dominator. J2778 sits lower at ranks #336 of 1208 (72th percentile; typical, unremarkable volume), indicating more modest positioning for ranibizumab relative to peers.

Several codes show volumes that are notably above typical national levels for non-drug services, which suggests a high procedural throughput: 67028 ranks #228 of 4255 providers nationally (95th percentile; notably above typical national volume for this code) and 92134 ranks #1461 of 26868 providers nationally (95th percentile; notably above typical national volume for this code). In addition, E/M code 99214 ranks #10197 of 479517 providers nationally (98th percentile; notably above typical national volume for this code), indicating the provider generates above-typical office-visit volume among Medicare peers.

There are a few low-penetration or atypical items in the mix: J3590 (unclassified biologics) appears only 22 claims with $50.8K revenue and ranks #563 of 631 providers nationally (9th percentile; typical, unremarkable volume for this code), reflecting limited use of unclassified biologics relative to national peers. J0179 (brolucizumab) has modest presence (396 claims, $97.8K revenue) and ranks #34 of 64 providers nationally (44th percentile; typical, unremarkable volume for this code), so newer or niche injectables are used but not at scale.

The provider’s revenue-per-claim profile underscores drug-administration dominance versus evaluation-and-management: high-revenue drug claims such as J0178 average $693 paid/claim and account for $1.6M of Medicare revenue, while a common E/M code 99214 (1K claims, $87 avg paid/claim, $91.1K revenue) contributes only 2.4% of Medicare receipts. This pattern is consistent with an infusion/injection-centric practice where drug and procedure fees drive the majority of public-payor revenue.

This NPI has an extended tenure in the Medicare program, having been enumerated on 2005-09-14 (~21 years ago), which supports continuity of billing patterns and may aid historical trend analysis; combine that longevity with the concentration in a few high-value intravitreal codes when evaluating contract negotiations, utilization reviews, or competitive benchmarking.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

14 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	2,360	$690	$1.6M
J2777	Injection, faricimab‑svoa, 0.1 mg	45,420	$30	$1.3M
J2778	Injection, ranibizumab, 0.1 mg	1,310	$180	$238.2K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,360	$90	$212.8K
J0179	Injection, brolucizumab-dbll, 1 mg	400	$250	$97.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,050	$90	$91.1K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	430	$150	$66.8K
J3590	Unclassified biologics	20	$2,310	$50.8K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	1,560	$30	$43.6K
J7999	Compounded drug, not otherwise classified	470	$70	$30.6K

Showing 1–10 of 14

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 14 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Mexico Distribution

Mark Chiu — 4 of 14 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Mexico

Full comparison — all codes billed, vs. state median

14 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	4	20	1,100	$690	$816.1K
J2777	3	20	17,340	$30	$653.4K
J2778	4	10	720	$180	$247.3K
J3590	5	10	30	$1,420	$97.9K
J0179	1	10	340	$250	$84.1K
67028	2	30	390	$90	$71.6K
J7312	3	10	310	$150	$50.2K
J7999	2	10	320	$60	$18.6K
92014	156	180	130	$70	$18.5K
99214	33	2,700	90	$70	$12.9K

Showing 1–10 of 14

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mark Chiu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Eye Associates Of New Mexico Ltd	NM	Ophthalmology Physician	$0	$46.9M
John Pitcher	NM	Ophthalmology Physician	$5.1M	$0
Christopher Roybal	NM	Ophthalmology Physician	$3.8M	$0
Ashok Reddy	NM	Ophthalmology Physician	$3.2M	$0
Kamalesh Ramaiya	NM	Ophthalmology Physician	$2.9M	$0
Betty Klein	NM	Ophthalmology Physician	$2.4M	$0
Rizwan Shaikh	LA	Ophthalmology Physician	$2.2M	$0
Iuri Golubev	NM	Ophthalmology Physician	$1.7M	$0
Eye Associates Of New Mexico, Ltd.	NM	Durable Medical Equipment & Medical Supplies	$0	$1.6M
Ian Thompson	NM	Ophthalmology Physician	$1.3M	$0

Nearby Providers

Other providers in the same ZIP code as Mark Chiu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tricore Reference Laboratories	NM	Clinical Medical Laboratory	$0	$64.8M
Bright Horizons, Inc.	NM	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$46.9M
Lovelace Health System LLC	NM	General Acute Care Hospital	$0	$45.2M
Tricore Inc.	NM	Clinical Medical Laboratory	$7M	$35.8M
App Of New Mexico Ed PLLC	NM	Emergency Medicine Physician	$0	$42M
Duke City Recovery Toolbox LLC	NM	Community/Behavioral Health Agency	$108.4K	$28M
Metro Treatment Of New Mexico LP	NM	Methadone Clinic	$220.4K	$27.9M
Enchanted Care Solutions, LLC	NM	Home Health Agency	$0	$25.8M
Open Skies Healthcare	NM	Community/Behavioral Health Agency	$0	$23.8M
Krossroads Integrative Health And Recovery Solutions Inc	NM	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$16.7M

Mark Chiu — Billing Profile & Reimbursement Data

Sign up for Mark Chiu — Billing Profile & Reimbursement Data policy alerts

Mark Chiu — Billing Profile & Reimbursement Data

Sign up for Mark Chiu — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References